Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Clinical Trials as Topic | 13 | 2024 | 8051 | 0.920 |
Why?
|
Electronic Health Records | 3 | 2024 | 4877 | 0.680 |
Why?
|
Glioblastoma | 13 | 2023 | 3524 | 0.520 |
Why?
|
Brain Neoplasms | 19 | 2023 | 9177 | 0.440 |
Why?
|
Feasibility Studies | 2 | 2024 | 5308 | 0.430 |
Why?
|
Camptothecin | 4 | 2003 | 594 | 0.400 |
Why?
|
Neoplasms | 14 | 2024 | 22389 | 0.400 |
Why?
|
Metagenomics | 1 | 2014 | 476 | 0.360 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2020 | 10358 | 0.330 |
Why?
|
Astrocytoma | 5 | 1999 | 780 | 0.320 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2010 | 300 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2020 | 11844 | 0.300 |
Why?
|
Medical Oncology | 6 | 2023 | 2347 | 0.270 |
Why?
|
Gene Regulatory Networks | 1 | 2014 | 1760 | 0.260 |
Why?
|
Models, Theoretical | 2 | 2017 | 3590 | 0.250 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5367 | 0.250 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4774 | 0.240 |
Why?
|
Sample Size | 2 | 2022 | 851 | 0.230 |
Why?
|
Statistics as Topic | 2 | 2010 | 2362 | 0.230 |
Why?
|
Bacteria | 1 | 2014 | 2226 | 0.220 |
Why?
|
Confidentiality | 1 | 2008 | 606 | 0.220 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4077 | 0.220 |
Why?
|
Meningococcal Infections | 1 | 2023 | 78 | 0.210 |
Why?
|
Biomedical Research | 4 | 2021 | 3463 | 0.210 |
Why?
|
Meningococcal Vaccines | 1 | 2023 | 96 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3116 | 0.200 |
Why?
|
Computational Biology | 1 | 2014 | 3549 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.200 |
Why?
|
Bone Marrow Transplantation | 14 | 2001 | 2702 | 0.200 |
Why?
|
Research Design | 8 | 2020 | 6217 | 0.200 |
Why?
|
Glioma | 6 | 2023 | 3523 | 0.190 |
Why?
|
Thinking | 1 | 2024 | 320 | 0.180 |
Why?
|
Lymphopenia | 1 | 2023 | 290 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 9 | 2015 | 5426 | 0.180 |
Why?
|
Exercise | 1 | 2017 | 5940 | 0.180 |
Why?
|
Cancer Vaccines | 2 | 2023 | 1044 | 0.180 |
Why?
|
Genomics | 1 | 2016 | 5912 | 0.170 |
Why?
|
Financing, Organized | 1 | 2021 | 206 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2011 | 9425 | 0.170 |
Why?
|
Antineoplastic Agents, Alkylating | 5 | 2011 | 618 | 0.170 |
Why?
|
Antineoplastic Agents | 9 | 2018 | 13709 | 0.170 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2020 | 139 | 0.170 |
Why?
|
Dacarbazine | 3 | 2011 | 560 | 0.160 |
Why?
|
Lung Neoplasms | 11 | 2020 | 13589 | 0.160 |
Why?
|
Cyclooxygenase Inhibitors | 3 | 2009 | 361 | 0.150 |
Why?
|
Humans | 107 | 2024 | 768369 | 0.150 |
Why?
|
Cerebral Revascularization | 1 | 2020 | 264 | 0.150 |
Why?
|
Algorithms | 2 | 2017 | 14157 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2014 | 330 | 0.130 |
Why?
|
Research Personnel | 1 | 2021 | 591 | 0.130 |
Why?
|
Multiple System Atrophy | 1 | 2017 | 130 | 0.130 |
Why?
|
Spouses | 1 | 1999 | 286 | 0.130 |
Why?
|
Supratentorial Neoplasms | 1 | 1997 | 159 | 0.130 |
Why?
|
Environmental Health | 1 | 1999 | 295 | 0.130 |
Why?
|
Stem Cell Research | 1 | 2016 | 37 | 0.130 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 890 | 0.130 |
Why?
|
Anticonvulsants | 3 | 2011 | 1923 | 0.130 |
Why?
|
Baltimore | 4 | 2010 | 234 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2020 | 971 | 0.120 |
Why?
|
Adenocarcinoma | 8 | 2020 | 6400 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2003 | 624 | 0.120 |
Why?
|
Language | 1 | 2024 | 1557 | 0.120 |
Why?
|
Carmustine | 4 | 2003 | 137 | 0.120 |
Why?
|
Cranial Irradiation | 3 | 2010 | 395 | 0.110 |
Why?
|
Sulfonamides | 3 | 2009 | 1988 | 0.110 |
Why?
|
Family Health | 1 | 1999 | 1256 | 0.110 |
Why?
|
Pleural Effusion, Malignant | 2 | 1994 | 108 | 0.110 |
Why?
|
Societies, Medical | 3 | 2023 | 3954 | 0.110 |
Why?
|
Radiotherapy | 2 | 2019 | 1510 | 0.110 |
Why?
|
Epistasis, Genetic | 1 | 2016 | 352 | 0.110 |
Why?
|
Pyrazoles | 3 | 2009 | 2024 | 0.110 |
Why?
|
Data Collection | 2 | 2020 | 3329 | 0.100 |
Why?
|
Nontherapeutic Human Experimentation | 1 | 2012 | 22 | 0.100 |
Why?
|
Drug Evaluation | 4 | 2005 | 642 | 0.100 |
Why?
|
Sialoglycoproteins | 1 | 2013 | 320 | 0.100 |
Why?
|
Neoplastic Stem Cells | 3 | 2013 | 1357 | 0.100 |
Why?
|
Immunotherapy | 4 | 2023 | 4728 | 0.100 |
Why?
|
Graft vs Host Disease | 8 | 2007 | 3042 | 0.100 |
Why?
|
Middle Aged | 54 | 2023 | 223406 | 0.100 |
Why?
|
Tetracyclines | 1 | 2011 | 64 | 0.090 |
Why?
|
Pain Measurement | 2 | 1992 | 3577 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2009 | 1794 | 0.090 |
Why?
|
Combined Modality Therapy | 13 | 2019 | 8559 | 0.090 |
Why?
|
Delaware | 1 | 2010 | 13 | 0.090 |
Why?
|
West Virginia | 1 | 2010 | 32 | 0.090 |
Why?
|
Placebos | 2 | 2012 | 1668 | 0.090 |
Why?
|
Antineoplastic Protocols | 1 | 2010 | 48 | 0.090 |
Why?
|
Virginia | 1 | 2010 | 115 | 0.090 |
Why?
|
Informed Consent | 3 | 2016 | 1012 | 0.090 |
Why?
|
Paclitaxel | 1 | 1997 | 1737 | 0.080 |
Why?
|
Communication | 1 | 2024 | 3910 | 0.080 |
Why?
|
Aged | 39 | 2020 | 171514 | 0.080 |
Why?
|
Haplotypes | 1 | 2016 | 2723 | 0.080 |
Why?
|
New Jersey | 1 | 2010 | 295 | 0.080 |
Why?
|
Maryland | 1 | 2010 | 277 | 0.080 |
Why?
|
Survival Analysis | 11 | 2013 | 10127 | 0.080 |
Why?
|
Pennsylvania | 1 | 2010 | 616 | 0.080 |
Why?
|
Databases, Factual | 3 | 2022 | 8081 | 0.080 |
Why?
|
Regression Analysis | 3 | 2014 | 6353 | 0.080 |
Why?
|
Adult | 48 | 2020 | 223528 | 0.080 |
Why?
|
Pentostatin | 1 | 2007 | 26 | 0.070 |
Why?
|
Prognosis | 22 | 2020 | 30031 | 0.070 |
Why?
|
Drug Combinations | 1 | 2014 | 2079 | 0.070 |
Why?
|
Ecology | 1 | 1988 | 105 | 0.070 |
Why?
|
Drug Discovery | 1 | 2015 | 1062 | 0.070 |
Why?
|
New York | 1 | 2010 | 881 | 0.070 |
Why?
|
Pancreatic Neoplasms | 3 | 2019 | 5443 | 0.070 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 424 | 0.070 |
Why?
|
Naproxen | 1 | 2007 | 101 | 0.070 |
Why?
|
Lymphoproliferative Disorders | 2 | 2000 | 531 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 7062 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2020 | 876 | 0.070 |
Why?
|
Treatment Outcome | 17 | 2020 | 65408 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2017 | 2901 | 0.070 |
Why?
|
Pain | 2 | 1992 | 5096 | 0.070 |
Why?
|
Male | 47 | 2023 | 364761 | 0.070 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 895 | 0.060 |
Why?
|
Heart Rate | 1 | 2017 | 4218 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2014 | 2359 | 0.060 |
Why?
|
Cisplatin | 5 | 1999 | 1661 | 0.060 |
Why?
|
Drug Interactions | 3 | 1998 | 1421 | 0.060 |
Why?
|
Models, Genetic | 1 | 2016 | 3442 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 1881 | 0.060 |
Why?
|
Female | 47 | 2023 | 396926 | 0.060 |
Why?
|
Mastectomy | 2 | 2007 | 1852 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2013 | 5893 | 0.060 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11249 | 0.060 |
Why?
|
Drug Administration Schedule | 5 | 2009 | 4861 | 0.060 |
Why?
|
Harderian Gland | 1 | 2004 | 3 | 0.060 |
Why?
|
Models, Statistical | 4 | 2005 | 5103 | 0.060 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2005 | 121 | 0.060 |
Why?
|
Patient Selection | 4 | 2015 | 4266 | 0.060 |
Why?
|
Ampulla of Vater | 1 | 2005 | 150 | 0.060 |
Why?
|
Cyclophosphamide | 9 | 2009 | 2224 | 0.060 |
Why?
|
Entropy | 1 | 2005 | 212 | 0.060 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2004 | 25 | 0.060 |
Why?
|
Patient Advocacy | 2 | 2017 | 362 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2015 | 3550 | 0.060 |
Why?
|
Linguistics | 1 | 2024 | 110 | 0.060 |
Why?
|
Karnofsky Performance Status | 3 | 2011 | 167 | 0.060 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2005 | 249 | 0.050 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2004 | 123 | 0.050 |
Why?
|
Epidemiologic Methods | 1 | 1988 | 1337 | 0.050 |
Why?
|
Stem Cells | 1 | 2016 | 3538 | 0.050 |
Why?
|
United States | 9 | 2023 | 73120 | 0.050 |
Why?
|
Neurodegenerative Diseases | 1 | 2012 | 1095 | 0.050 |
Why?
|
Biliary Tract Neoplasms | 1 | 2005 | 187 | 0.050 |
Why?
|
Barrett Esophagus | 1 | 2007 | 494 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 1997 | 2228 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2437 | 0.050 |
Why?
|
Safety Management | 1 | 2008 | 764 | 0.050 |
Why?
|
Information Dissemination | 2 | 2008 | 1138 | 0.050 |
Why?
|
Suramin | 1 | 2001 | 34 | 0.050 |
Why?
|
Urban Population | 1 | 2010 | 2047 | 0.050 |
Why?
|
Sleep | 1 | 2017 | 4796 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 334 | 0.050 |
Why?
|
Stroke | 2 | 2020 | 9790 | 0.050 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9261 | 0.050 |
Why?
|
Emphysema | 1 | 2004 | 238 | 0.050 |
Why?
|
Prostatectomy | 3 | 2003 | 1840 | 0.050 |
Why?
|
Prostate | 1 | 2009 | 1781 | 0.050 |
Why?
|
Neurosurgical Procedures | 1 | 2012 | 2096 | 0.050 |
Why?
|
Treatment Failure | 3 | 2007 | 2655 | 0.050 |
Why?
|
Software | 1 | 2014 | 4465 | 0.040 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2004 | 555 | 0.040 |
Why?
|
Hodgkin Disease | 3 | 2001 | 1386 | 0.040 |
Why?
|
Culture | 1 | 2024 | 624 | 0.040 |
Why?
|
Prostatic Neoplasms | 5 | 2009 | 11206 | 0.040 |
Why?
|
Leukemia | 2 | 2007 | 1527 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8751 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2007 | 988 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2014 | 10784 | 0.040 |
Why?
|
Uncertainty | 1 | 2005 | 758 | 0.040 |
Why?
|
Transplantation, Autologous | 8 | 2001 | 2126 | 0.040 |
Why?
|
B-Lymphocyte Subsets | 1 | 2000 | 240 | 0.040 |
Why?
|
Immunotherapy, Adoptive | 1 | 2009 | 1505 | 0.040 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2019 | 28 | 0.040 |
Why?
|
Antisickling Agents | 1 | 1999 | 72 | 0.040 |
Why?
|
Actuarial Analysis | 6 | 2001 | 372 | 0.040 |
Why?
|
Transplantation | 1 | 2000 | 221 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1992 | 1557 | 0.040 |
Why?
|
Radiometry | 1 | 2004 | 816 | 0.040 |
Why?
|
Propionates | 1 | 1999 | 180 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2004 | 1727 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2001 | 784 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2007 | 1891 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2000 | 621 | 0.040 |
Why?
|
Lung Diseases, Obstructive | 1 | 1999 | 311 | 0.040 |
Why?
|
Brain | 2 | 2024 | 27439 | 0.040 |
Why?
|
Nevada | 1 | 2017 | 22 | 0.040 |
Why?
|
Models, Animal | 1 | 2005 | 2126 | 0.040 |
Why?
|
Receptors, AMPA | 2 | 2010 | 335 | 0.040 |
Why?
|
Retreatment | 1 | 2000 | 601 | 0.040 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39429 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2000 | 438 | 0.040 |
Why?
|
Aged, 80 and over | 11 | 2020 | 59679 | 0.040 |
Why?
|
Survival Rate | 7 | 2010 | 12875 | 0.040 |
Why?
|
Viremia | 1 | 2000 | 715 | 0.040 |
Why?
|
Recurrence | 7 | 2007 | 8510 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2000 | 631 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8636 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 1480 | 0.040 |
Why?
|
Mortality | 1 | 1988 | 2917 | 0.040 |
Why?
|
Disease-Free Survival | 6 | 2007 | 6856 | 0.030 |
Why?
|
Adolescent | 16 | 2010 | 89163 | 0.030 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2019 | 344 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2019 | 427 | 0.030 |
Why?
|
Republic of Korea | 1 | 2019 | 587 | 0.030 |
Why?
|
Sputum | 1 | 1999 | 511 | 0.030 |
Why?
|
Esophageal Neoplasms | 1 | 2007 | 1676 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16712 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 1993 | 7449 | 0.030 |
Why?
|
Breast Neoplasms | 4 | 2009 | 21157 | 0.030 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20232 | 0.030 |
Why?
|
Remission Induction | 4 | 2005 | 2408 | 0.030 |
Why?
|
Arteriosclerosis | 1 | 2000 | 1056 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2005 | 2431 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2005 | 2058 | 0.030 |
Why?
|
Outpatients | 1 | 2023 | 1607 | 0.030 |
Why?
|
Fluorouracil | 3 | 1991 | 1656 | 0.030 |
Why?
|
Prostate-Specific Antigen | 2 | 2003 | 2483 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2019 | 726 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2016 | 223 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2001 | 1308 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2705 | 0.030 |
Why?
|
Random Allocation | 2 | 1992 | 2399 | 0.030 |
Why?
|
Consent Forms | 1 | 1994 | 55 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2000 | 1376 | 0.030 |
Why?
|
Specimen Handling | 1 | 1999 | 709 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4213 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8372 | 0.030 |
Why?
|
Whole-Body Irradiation | 2 | 1992 | 434 | 0.030 |
Why?
|
Child | 16 | 2010 | 80856 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2000 | 616 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 888 | 0.030 |
Why?
|
Transplantation, Homologous | 4 | 2001 | 4834 | 0.030 |
Why?
|
Time Factors | 6 | 2011 | 40271 | 0.030 |
Why?
|
Animals | 4 | 2024 | 169424 | 0.030 |
Why?
|
Gastrectomy | 1 | 2019 | 696 | 0.030 |
Why?
|
Aniline Compounds | 1 | 1999 | 1094 | 0.030 |
Why?
|
Bone Marrow | 3 | 2005 | 2929 | 0.030 |
Why?
|
Benzodiazepines | 2 | 2010 | 1139 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 864 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1795 | 0.030 |
Why?
|
Incidence | 3 | 2019 | 21552 | 0.030 |
Why?
|
Cytarabine | 2 | 1994 | 697 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2001 | 928 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2022 | 2324 | 0.030 |
Why?
|
Drug Resistance | 3 | 2007 | 1599 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2003 | 15965 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4931 | 0.020 |
Why?
|
Busulfan | 2 | 1992 | 259 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 1997 | 1014 | 0.020 |
Why?
|
Ethics | 1 | 1992 | 94 | 0.020 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 37 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2023 | 2753 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2010 | 5508 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2021 | 1600 | 0.020 |
Why?
|
Bone Marrow Purging | 1 | 1991 | 108 | 0.020 |
Why?
|
SOXB1 Transcription Factors | 1 | 2013 | 286 | 0.020 |
Why?
|
Retrospective Studies | 11 | 2023 | 81835 | 0.020 |
Why?
|
Spheroids, Cellular | 1 | 2013 | 332 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 2020 | 1179 | 0.020 |
Why?
|
Writing | 1 | 1993 | 200 | 0.020 |
Why?
|
Ploidies | 1 | 1992 | 287 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 1991 | 3623 | 0.020 |
Why?
|
Computer Simulation | 1 | 2005 | 6278 | 0.020 |
Why?
|
Prospective Studies | 4 | 2023 | 54913 | 0.020 |
Why?
|
Reading | 1 | 1994 | 543 | 0.020 |
Why?
|
Interferon Inducers | 1 | 2010 | 24 | 0.020 |
Why?
|
Analysis of Variance | 6 | 2000 | 6242 | 0.020 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2010 | 38 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3939 | 0.020 |
Why?
|
Snake Venoms | 1 | 2010 | 40 | 0.020 |
Why?
|
gamma-Globulins | 1 | 1990 | 119 | 0.020 |
Why?
|
Hospitals, University | 1 | 1992 | 569 | 0.020 |
Why?
|
Growth | 1 | 1992 | 366 | 0.020 |
Why?
|
Poly I-C | 1 | 2010 | 111 | 0.020 |
Why?
|
Polylysine | 1 | 2010 | 131 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1992 | 1629 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2011 | 6537 | 0.020 |
Why?
|
Proportional Hazards Models | 6 | 2009 | 12561 | 0.020 |
Why?
|
Models, Biological | 1 | 1985 | 9505 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 1609 | 0.020 |
Why?
|
Comprehension | 1 | 1994 | 641 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1909 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 1644 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2009 | 210 | 0.020 |
Why?
|
Immunization Schedule | 1 | 2009 | 227 | 0.020 |
Why?
|
Neuroendocrine Tumors | 1 | 1994 | 650 | 0.020 |
Why?
|
Child, Preschool | 11 | 2007 | 42620 | 0.020 |
Why?
|
Hydrazines | 1 | 1990 | 223 | 0.020 |
Why?
|
Erythropoietin | 1 | 1992 | 719 | 0.020 |
Why?
|
Lymph Nodes | 1 | 1999 | 3472 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2005 | 7895 | 0.020 |
Why?
|
Anemia | 2 | 1999 | 1521 | 0.020 |
Why?
|
Nursing Staff, Hospital | 1 | 1991 | 350 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2009 | 347 | 0.020 |
Why?
|
Mathematics | 1 | 1988 | 704 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 1993 | 1749 | 0.020 |
Why?
|
Mutation | 2 | 2019 | 30235 | 0.020 |
Why?
|
Thrombocytopenia | 2 | 1999 | 1183 | 0.020 |
Why?
|
Aortic Valve Stenosis | 1 | 2000 | 2031 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 637 | 0.020 |
Why?
|
Cyclooxygenase 1 | 1 | 2007 | 98 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2011 | 2298 | 0.020 |
Why?
|
Herpes Zoster | 1 | 1989 | 253 | 0.020 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2009 | 452 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 1991 | 603 | 0.020 |
Why?
|
Brain Ischemia | 1 | 2000 | 3038 | 0.020 |
Why?
|
Doxorubicin | 2 | 2009 | 2229 | 0.020 |
Why?
|
Nootropic Agents | 1 | 2007 | 159 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4582 | 0.020 |
Why?
|
HLA Antigens | 2 | 2007 | 1333 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8723 | 0.020 |
Why?
|
Infant | 7 | 1999 | 36496 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2023 | 26394 | 0.020 |
Why?
|
Selection Bias | 1 | 2007 | 360 | 0.020 |
Why?
|
Age Factors | 4 | 1996 | 18477 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2011 | 2589 | 0.020 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2005 | 88 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1992 | 1539 | 0.010 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2005 | 130 | 0.010 |
Why?
|
RNA-Binding Proteins | 1 | 2013 | 1885 | 0.010 |
Why?
|
Lymphoma | 2 | 1991 | 1907 | 0.010 |
Why?
|
Mesothelioma | 1 | 1991 | 811 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2007 | 599 | 0.010 |
Why?
|
Receptors, Retinoic Acid | 1 | 2005 | 229 | 0.010 |
Why?
|
Cell Division | 1 | 1992 | 4479 | 0.010 |
Why?
|
Clinical Protocols | 2 | 2004 | 1444 | 0.010 |
Why?
|
DNA Methylation | 2 | 2009 | 4425 | 0.010 |
Why?
|
Ions | 1 | 2004 | 257 | 0.010 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12096 | 0.010 |
Why?
|
Family | 1 | 1994 | 3208 | 0.010 |
Why?
|
Cluster Analysis | 1 | 1990 | 2730 | 0.010 |
Why?
|
Linear Energy Transfer | 1 | 2004 | 154 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1992 | 2889 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2010 | 1395 | 0.010 |
Why?
|
Decision Making, Organizational | 1 | 2004 | 136 | 0.010 |
Why?
|
Anthracyclines | 1 | 2005 | 286 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 6320 | 0.010 |
Why?
|
Survival | 1 | 2003 | 161 | 0.010 |
Why?
|
Pedigree | 1 | 1990 | 4545 | 0.010 |
Why?
|
Stomatitis | 1 | 2005 | 271 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2004 | 882 | 0.010 |
Why?
|
Postoperative Complications | 4 | 2000 | 15879 | 0.010 |
Why?
|
Psychometrics | 1 | 1992 | 3072 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3586 | 0.010 |
Why?
|
Cadherins | 1 | 2007 | 906 | 0.010 |
Why?
|
Biometry | 1 | 1985 | 565 | 0.010 |
Why?
|
Tretinoin | 1 | 2005 | 525 | 0.010 |
Why?
|
Fellowships and Scholarships | 1 | 1991 | 1134 | 0.010 |
Why?
|
Preoperative Care | 1 | 1991 | 2257 | 0.010 |
Why?
|
Transfection | 1 | 2009 | 5767 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2007 | 1276 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 4040 | 0.010 |
Why?
|
Mass Media | 1 | 2004 | 304 | 0.010 |
Why?
|
Absorbable Implants | 1 | 2003 | 339 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2013 | 4417 | 0.010 |
Why?
|
Photons | 1 | 2004 | 594 | 0.010 |
Why?
|
Filgrastim | 1 | 2000 | 132 | 0.010 |
Why?
|
Hemoglobins | 2 | 1999 | 1532 | 0.010 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2004 | 794 | 0.010 |
Why?
|
Lymphocyte Transfusion | 1 | 2000 | 232 | 0.010 |
Why?
|
Chronic Disease | 3 | 2003 | 9379 | 0.010 |
Why?
|
Odds Ratio | 1 | 1992 | 9687 | 0.010 |
Why?
|
Carcinoma | 1 | 1991 | 2341 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 2005 | 926 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1640 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2009 | 2819 | 0.010 |
Why?
|
Protons | 1 | 2004 | 1112 | 0.010 |
Why?
|
Vidarabine | 1 | 2000 | 337 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2586 | 0.010 |
Why?
|
Virus Activation | 1 | 2000 | 322 | 0.010 |
Why?
|
Risk Factors | 8 | 2004 | 74915 | 0.010 |
Why?
|
Leukopenia | 1 | 1999 | 214 | 0.010 |
Why?
|
Brain Edema | 1 | 2003 | 608 | 0.010 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2000 | 435 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2896 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 1991 | 4083 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2013 | 10490 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 695 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2005 | 2415 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2279 | 0.010 |
Why?
|
Aorta, Abdominal | 1 | 2000 | 627 | 0.010 |
Why?
|
Lymphatic Metastasis | 2 | 1999 | 2930 | 0.010 |
Why?
|
Genome, Viral | 1 | 2000 | 671 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1991 | 3922 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 4403 | 0.010 |
Why?
|
Axilla | 1 | 1999 | 629 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 17149 | 0.010 |
Why?
|
Organ Specificity | 1 | 2001 | 1974 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11674 | 0.010 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2001 | 712 | 0.010 |
Why?
|
Polymers | 1 | 2003 | 1631 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15610 | 0.010 |
Why?
|
Risk Assessment | 2 | 2009 | 24310 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 12450 | 0.010 |
Why?
|
Gastrin-Releasing Peptide | 1 | 1994 | 36 | 0.010 |
Why?
|
Chromogranin A | 1 | 1994 | 47 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2000 | 1081 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 2005 | 1400 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 2003 | 1703 | 0.010 |
Why?
|
Disease Progression | 2 | 2003 | 13643 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 1999 | 878 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1994 | 127 | 0.010 |
Why?
|
Pleurodesis | 1 | 1994 | 49 | 0.010 |
Why?
|
Ischemic Attack, Transient | 1 | 2000 | 879 | 0.010 |
Why?
|
Skin Diseases | 1 | 2003 | 1099 | 0.010 |
Why?
|
Chromogranins | 1 | 1994 | 160 | 0.010 |
Why?
|
Vimentin | 1 | 1994 | 257 | 0.010 |
Why?
|
Injections, Intralesional | 1 | 1994 | 281 | 0.010 |
Why?
|
Case-Control Studies | 1 | 1992 | 22286 | 0.010 |
Why?
|
DNA, Viral | 1 | 2000 | 2203 | 0.010 |
Why?
|
Echocardiography, Transesophageal | 1 | 2000 | 1095 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 1994 | 338 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2004 | 8201 | 0.010 |
Why?
|
Diploidy | 1 | 1993 | 134 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1999 | 2103 | 0.010 |
Why?
|
Carotid Stenosis | 1 | 2000 | 864 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9642 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2001 | 5708 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2007 | 12813 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 1991 | 116 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 1994 | 919 | 0.010 |
Why?
|
Pilot Projects | 1 | 2005 | 8730 | 0.010 |
Why?
|
Somatomedins | 1 | 1992 | 179 | 0.010 |
Why?
|
Viral Load | 1 | 2000 | 3374 | 0.010 |
Why?
|
Hospitalization | 1 | 2011 | 10845 | 0.010 |
Why?
|
Lymphocytes | 1 | 1999 | 2611 | 0.010 |
Why?
|
Bilirubin | 1 | 1992 | 439 | 0.010 |
Why?
|
Radiation Dosage | 1 | 1999 | 1974 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6527 | 0.010 |
Why?
|
Methylprednisolone | 1 | 1991 | 387 | 0.010 |
Why?
|
Seizures | 1 | 2003 | 2996 | 0.010 |
Why?
|
Philadelphia Chromosome | 1 | 1990 | 119 | 0.010 |
Why?
|
Glucagon | 1 | 1992 | 534 | 0.010 |
Why?
|
Growth Hormone | 1 | 1992 | 573 | 0.010 |
Why?
|
Cyclosporine | 1 | 1992 | 781 | 0.010 |
Why?
|
Tissue Preservation | 1 | 1990 | 174 | 0.010 |
Why?
|
Vincristine | 1 | 1991 | 1039 | 0.010 |
Why?
|
Skin Diseases, Infectious | 1 | 1989 | 76 | 0.010 |
Why?
|
Aneuploidy | 1 | 1993 | 572 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 19035 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1989 | 352 | 0.010 |
Why?
|
Freezing | 1 | 1990 | 311 | 0.000 |
Why?
|
Premedication | 1 | 1989 | 246 | 0.000 |
Why?
|
Herpesvirus 3, Human | 1 | 1989 | 159 | 0.000 |
Why?
|
Artificial Intelligence | 1 | 2003 | 2659 | 0.000 |
Why?
|
Rats | 1 | 2004 | 23839 | 0.000 |
Why?
|
Blood Chemical Analysis | 1 | 1990 | 436 | 0.000 |
Why?
|
Azathioprine | 1 | 1989 | 354 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1990 | 1379 | 0.000 |
Why?
|
Predictive Value of Tests | 2 | 1995 | 15459 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1990 | 20763 | 0.000 |
Why?
|
Platelet Count | 1 | 1990 | 786 | 0.000 |
Why?
|
Cohort Studies | 2 | 2003 | 41782 | 0.000 |
Why?
|
Gene Rearrangement | 1 | 1991 | 1139 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1990 | 1604 | 0.000 |
Why?
|
Body Height | 1 | 1992 | 1568 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2001 | 14766 | 0.000 |
Why?
|
Prednisone | 1 | 1989 | 1568 | 0.000 |
Why?
|
Cell Cycle | 1 | 1993 | 2942 | 0.000 |
Why?
|
Probability | 1 | 1990 | 2483 | 0.000 |
Why?
|
Chi-Square Distribution | 1 | 1990 | 3438 | 0.000 |
Why?
|
Methotrexate | 1 | 1990 | 1722 | 0.000 |
Why?
|
Young Adult | 1 | 2010 | 60038 | 0.000 |
Why?
|
Peptides | 1 | 1994 | 4368 | 0.000 |
Why?
|
Attitude to Health | 1 | 1990 | 2030 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1994 | 11139 | 0.000 |
Why?
|
Patient Education as Topic | 1 | 1990 | 2339 | 0.000 |
Why?
|
Hemodynamics | 1 | 1990 | 4202 | 0.000 |
Why?
|
Acute Disease | 1 | 1989 | 7245 | 0.000 |
Why?
|
Graft Survival | 1 | 1989 | 3890 | 0.000 |
Why?
|
Physician-Patient Relations | 1 | 1990 | 3267 | 0.000 |
Why?
|
Hematopoietic Stem Cells | 1 | 1989 | 3408 | 0.000 |
Why?
|
Palliative Care | 1 | 1990 | 3644 | 0.000 |
Why?
|
Quality of Life | 1 | 1990 | 13497 | 0.000 |
Why?
|